Global Lichen Planus Market, By Treatment Type (Retinoids, Corticosteroids, Antihistamines, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Lichen Planus Market Analysis and Size
The global lichen planus market is expected to witness significant growth during the forecast period. Lichen planus affects around 1% of the population globally, typically affecting adults aged 30 to 60 years. It has no strong racial predilection. Contributing factors of this disease are genetic predisposition, physical and emotional stress, injury to the skin. It has been noticed that many cases of skin lichen planus go away within two years. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global lichen planus market in the forecast period 2022-2029. The expected CAGR of global lichen planus market is tend to be around 7.50% in the mentioned forecast period. The market was valued at USD 120 million in 2021, and it would grow upto USD 214.02 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lichen Planus Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Retinoids, Corticosteroids, Antihistamines, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Zydus Group (India), Hikma Pharmaceuticals PLC (U.K.), LEO Pharma A/S (Denmark)
|
|
Market Opportunities
|
|
Market Definition
Lichen planus is also known as lichen ruber planus and is defined as rare, chronic, inflammatory autoimmune disorder of the skin and mucous membrane. It is typically characterized by swelling and severe irritation in the area of the skin, hair, nails and mucous membranes. Lichen planus generally appears on the skin as purplish, itchy, flat bumps which develop over several weeks. People with hepatitis C are more prone to lichen planus. Treatment for this condition include antihistamines, phototherapy, or steroid creams.
Global Lichen Planus Market Dynamics
Drivers
- Increase in the prevalence of hepatitis C
The global lichen planus market is mainly driven by high incidence of lichen planus. About 1% of the world’s population is affected by lichen planus. People affected with hepatitis C are more prone to the condition. Therefore, rise in the number of patients with hepatitis C is the main driver of the global lichen planus market.
- Rise in Demand of Corticosteroids
Corticosteroids are used as first-line treatment for lichen planus and other inflammatory disorders. Among them, topical corticosteroids are most frequently used in the treatment of the condition. Corticosteroid drugs are used to relieve the symptoms of itching and rashes. In addition to this, immunomodulators are widely used in the treatment of extreme cases of lichen planus. This increasing demand boosts the market growth.
Opportunities
- Preference for Topical Route of Administration
Among the different routes of administration, the topical route is expected to dominate the global market during the forecast period. Topical is considered the most commonly used and favoured route of administration of the treatment of lichen planus as the recovery is faster and easily feasible. Thus, this demand of topical drugs increases the market size.
- Increasing Demand for Retail Pharmacies
The increase in the number of drugs for lichen planus delivered through retail pharmacies and the increase in the number of retail pharmacies in highly economic countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of Awareness
The lack of awareness among patients and doctors about the lichen planus is a major restraint. The underdeveloped and developing countries are unaware of rare conditions such as Nateglinide. Many mix this condition with other skin and autoimmune disorders. However, no proper treatment for the disorder deteriorates the emotional status and needs of the patient. Much more research and awareness about these rare diseases are required in many counties.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth. These retinoids, corticosteroids, and antihistamines are expensive, and the price is increasing with each decade. Thus, this factor hamper the market growth.
- Lack of Proper Medication
Lack of appropriate medications and treatment is expected to increase this medical condition's effects. According to the market analysis, less awareness can lead to a small adoption rate of Olanzapine drugs. Thus, these factors can restrict the total demand for the lichen planus market during the forecast period.
This global lichen planus market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global lichen planus market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Lichen Planus Market Scope
The global lichen planus market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Retinoids
- Tretinoin
- Retinyl palmitate
- Retinaldehyde
- Corticosteroids
- Aristocort.
- Bubbli-Pred.
- Celestone
- Antihistamines
- Azelastine
- Loratadine
- Cetirizine
- Others
Route of Administration
- Oral
- Topical
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Lichen Planus Market Regional Analysis/Insights
The global lichen planus market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global lichen planus market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing the highest growth for the global lichen planus market throughout the forecasted period due to the presence of key generic players and rapidly disposable income.
North America dominates the market due to the high disposable income and advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Lichen Planus Market Share Analysis
The global lichen planus market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global lichen planus market.
Key players operating in the global lichen planus market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Zydus Group (India)
- Hikma Pharmaceuticals PLC (U.K.)
- LEO Pharma A/S (Denmark)
SKU-